2. 尊龙凯时

    Overview
    CURRENT LOCATION: HOME > R&D and Innovation > Overview
    OVERVIEW
    01

    R&D Directions

    02

    R&D Projects

    03

    Intellectual Property

    04

    Innovative Platform

    05

    Innovative Talents

    The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.

    More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.

    The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.

    The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, China.

    The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.

    While building a first-class platform for R&D and innovation, the company provides all-around service from research, development, and clinical trials to registration of new drugs.

    The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.

    Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and 7 experts enjoying a special allowance of The State Council.

    The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.
    More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.
    The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, Chi
    The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.While building a first-class platform for R&D and innovation, the
    The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and

    Development Progress

    R&D Centers

    Technology Platform
    Technology platform for innovative small molecule drugs

    Design of novel molecules that are non-addictive and non-respiratory depressant.

    Technology platform for long-acting microspheres and liposomes

    Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.

    Technology platform for transdermal administration

    Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.

    Technology platform for anti-abuse design of special drugs

    Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.